

INNOVUS PHARMACEUTICALS, INC.

Form 8-K

January 23, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 20, 2018

INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

| | | |
|--|-----------------------------|-----------------------------------|
| Nevada | 000-52991 | 90-0814124 |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

| | |
|--|------------|
| 8845 Rehco Road, San Diego, CA | 92122 |
| (Address of Principal Executive Offices) | (Zip Code) |

Registrant's telephone number, including area code: (858) 249-7873

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” the “Company”, “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 8.01 – Other Events

On January 23, 2018, the Company issued a press release announcing that it had entered into an exclusive license and distribution agreement with Lavasta Pharma FZ-LLC, a Dubai company for the distribution of its ProstaGorx® product in certain countries in the Middle East and North Africa. Pursuant to the Lavasta agreement, Lavasta shall receive an upfront payment plus a transfer price on Lavasta’s minimum annual purchase requirements.

The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 -- Financial Statements and Exhibits

(d) Exhibits

| Exhibit Number | Description |
|----------------|--|
| <u>99.1</u> | Press release issued January 23, 2018. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

INNOVUS PHARMACEUTICALS, INC.

Date: January 23, 2018 By: /s/ Randy Berholtz
Randy Berholtz
EVP, Corporate Development

EXHIBIT INDEX

| Exhibit No. | Description |
|-------------|---------------------------------------|
| 99.1 | Press release issued January 23, 2018 |